3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Recruiting
2
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Gastrointestinal
2
Conditions
Colorectal Neoplasms
119
Carcinoma, Hepatocellular
69
Ovarian Neoplasms
62
Neoplasms
36
Carcinoma, Non-Small-Cell Lung
34
Fallopian Tube Neoplasms
29
Brain Neoplasms
24
Glioblastoma
22
Colonic Neoplasms
21
Breast Neoplasms
19
Neoplasm Metastasis
18
Endometrial Neoplasms
18
Stomach Neoplasms
15
Uterine Cervical Neoplasms
14
Rectal Neoplasms
14
Lung Neoplasms
14
Liver Neoplasms
11
Triple Negative Breast Neoplasms
10
Melanoma
8
Glioma
8
Carcinoma, Renal Cell
8
Carcinoma, Ovarian Epithelial
8
Biliary Tract Neoplasms
8
Colorectal Cancer Metastatic
7
Squamous Cell Carcinoma of Head and Neck
6
Recurrence
6
Parkinson Disease 4, Autosomal Dominant Lewy Body
6
Gastrointestinal Neoplasms
6
Advanced Solid Tumors
6
Small Cell Lung Carcinoma
5
Interventions
atezolizumab
2
Control Groups
2
Blood Specimen Collection
2
Bevacizumab
2
repotrectinib
1
pembrolizumab
1
durvalumab
1
User-Centered Design
1
Standard of Care
1
Patient Navigation
1
Neuropsychological Tests
1
Neoadjuvant Therapy
1
Liver Transplantation
1
Injections
1
Immunotherapy
1
Electroporation
1
Catheter Ablation
1
Adjuvants, Pharmaceutic
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Liver Diseases
×
Bevacizumab
×
1 year
×
Clear all
NCT06096779
2026-06-01
Kirros
Genentech, Inc.
Phase 2
Recruiting
30 enrolled
NCT04727307
2025-09-30
AB-LATE02
University Hospital, Montpellier
Phase 2
Recruiting
202 enrolled